The global DNA sequencing market size reached USD 11.13 billion in 2023 and is estimated to attain around USD 51.31 billion by 2034, at a CAGR of 14.9% from 2024 to 2034.
DNA Sequencing Market Highlights:
- North America dominated the DNA sequencing market with the largest market share of 51% in 2023.
- Asia Pacific is expected to grow at the fastest rate during the forecast period.
- By product, the consumable segment led the market in 2023.
- By technology, the next-generation sequencing segment dominated the market in 2023.
- By application, the oncology segment contributed the largest market share in 2023.
- By end-use, the academic research segment dominated the market in 2023.
DNA Sequencing Market Overview
Advancements in sequencing technology have enabled researchers to provide high-volume data on genetic variation and gene expression. Next-generation sequencing (NGS), which has become increasingly popular, offers several advantages in terms of high throughput, lower cost, speed, data resolution, versatility, accuracy, and the ability to detect rare genetic variants.
Fast turnaround time, high-resolution data, versatility, and accuracy make next-generation sequencing appropriate for various applications. Its ability to detect rare genetic variations is vital in understanding disease mechanisms, treatment tailoring, and prognosis. The adoption of NGS is projected to increase rapidly, with continuous improvement in sequencing accuracy, read length, miniaturization, and portability.
Get a Sample: https://www.precedenceresearch.com/sample/1189
DNA Sequencing Market Analysis by Regions
North America dominated the market in 2023 owing to the presence of well-established healthcare infrastructure. Moreover, the presence of a large number of market players fuels the growth of the market in the region. These players are making efforts to boost their market presence. The rising genomics, oncology, and whole-genome-based research further propel the market. Other factors such as increasing research programs, funding, availability of skilled personnel, and companies thrusting for better research methods to identify new technologies for diagnosis and therapies fuel the market.
The market in Asia Pacific is expected to grow at the fastest rate during the forecast period.
The growth of the Asia Pacific market is primarily driven by developments in prenatal NGS testing. NGS testing enable early diagnosis of rare diseases and pathogen monitoring, thereby improving outcomes for cancer patients. Moreover, the increasing developments in genomics boost the market.
- In August 2024, the government of Kerala decided to use advanced DNA sequencing technology to identify victims of Wayanad landslides. This technology will be used to identify 32 decomposed samples recovered from landslide-hit areas in Mundakkai-Chooralmala.
Market Scope
| Report Highlights | Details |
| Growth Rate from 2024 to 2034 | CAGR of 14.9% |
| Market Size in 2023 | USD 11.13 billion |
| Market Size in 2024 | USD 12.79 billion |
| Market Size by 2034 | USD 51.31 billion |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2023 |
| Forecast Period | 2024 to 2034 |
| Segments Covered | Product, technology, Application, and End Use |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
DNA Sequencing Market Segment Analysis
Analysis by Product
The consumable segment accounted for the largest market share in 2023.
The sequencing consumables form the intrinsic part of DNA sequencing processes through reagents, kits, and other associated products. The genomic advancements and broad adoption of next-generation sequencing technologies in research, clinical diagnostics, and personalized medicine applications raise the demand for sequencing consumables.
The sequencing consumables segment is likely to continue expanding due to the increasing integration of genomics into biomedical research, rising technological advancements, and a global push toward more personalized genomic approaches.
- For instance, in February 2023, Oxford Nanopore Technologies extended its partnership with UPS Healthcare to speed up the delivery of DNA/RNA sequencing products and consumables throughout the Asia Pacific, increasing supply while enabling more time for research in genomics.
Analysis by Technology
The next-generation sequencing segment led the DNA sequencing market in 2023.
Next-generation sequencing technology is important for studying DNA and other genetic material, requiring the quick and accurate sequencing of large stretches of DNA. Laboratory automation is essential for increasing the efficiency and accuracy of the sequencing process.
Next-generation sequencing accelerates the process, saving considerable time and resources while sequencing large stretches of DNA. This allows researchers to process more samples within a short period, ensuring that the results are accurate and consistent.
- In March 2024, NGeneBio and Genolution signed a memorandum of understanding to develop and launch an automated next-generation sequencing system.
Analysis by Application
The oncology segment held a major share of the market in 2023.
Next-generation sequencing is revolutionizing cancer treatments by providing exact and detailed data on individual tumors. NGS-driven diagnostics is driving treatment selection to optimize patient outcomes.
Next-generation sequencing brings improved accuracy and speed in diagnosis, which holds substantial implications for oncology by allowing the assessment of multiple genes within a single assay and obviates the need for running multiple tests in search of causative mutations. This multigene approach reduces the time to answer, provides a more economical solution, and allows for high sensitivity, enabling mutation detection at as low as 5% of DNA isolated from a tumor sample.
Analysis by End-use
The academic research segment dominated the market in 2023 due to the heightened adoption of Sanger technology and NGS in research projects. Funding and investment programs have increased the demand for DNA sequencing products and services.
Additionally, the increasing research activities on disease and personalized therapies are likely to boost the segment.
Read Also: Cell and Gene Therapy Market Size to Cross USD 117.46 Bn By 2034
DNA Sequencing Market Dynamics
Driver
The advent of next-generation sequencing (NGS)
In the last decade, scientific research and clinical genomics applications have been significantly revolutionized by NGS due to its high throughput multiplexing, coupled with smart bioinformatic tools. Various population genome sequencing projects such as 1000 G, ExAC, ESP6500, UK 100 K, Indigenome, and gnomAD generated huge data on NGS, leading to the development of knowledge bases and large and small sequencing panels for major applications in clinical research and diagnostics.
NGS is heavily used in microbiome research, human disease research, and diagnostics. NGS further assists in transcriptomic pathogen analysis, metastatic biomarkers, therapeutic resistance, immune microenvironment and immunotherapy, and cancer neoantigen research. NGS is also useful in diagnostics for precisely identifying the etiological agent in microbial infections and finding a correlation among many genes in multifactorial disorders.
- In May 2024, Ambry Genetics and PacBio announced that they are conducting a large, rare disease genome sequencing project in collaboration with the University of California, Irvine (UCI) and the GREGoR Consortium (Genomics Research to Elucidate the Genetics of Rare diseases).
- In November 2023, Johnson & Johnson collaborated with the world’s biggest human genome sequencing project to increase understanding of genetic diseases among scientists and develop new healthcare interventions.
Restraint
Low quality of outsourcing services
Outsourcing becomes imperative for developing countries where genome sequencing facilities are limited. The outsourcing companies that become the local representatives for some foreign companies supply low-quality services. They send samples to be sequenced and send results back.
Improper handling and transport and long service timing lead to low-quality service. It consumes a lot of money and time, sometimes running into months, and may fail at any stage. Thus, outsourcing is the only option for accessing Balize genomic technologies in such countries.
Opportunity
Development of personalized therapy
The genome analysis and sequencing technology is likely to spread to all other research areas as it improves diagnostic procedures, thus permitting the establishment of personalized therapies. DNA sequencing methods have been applied in diagnosing complex neuro-developmental disorders and tumors, thus helping pregnant women avoid invasive methods, such as amniocenteses.
The wide availability of cheap and high-performance sequencing techniques is expected to increase the diversity of genomic research and applications. Scientists are focusing on enhancing the sequencing technique with more efficiency, accuracy, and less processing time.
DNA Sequencing Market Companies
- Agilent Technologies
- Illumina, Inc.
- QIAGEN
- Perkin Elmer
- Thermo Fisher Scientific
- Hoffmann-La Roche Ltd.
- Macrogen, Inc.
- Bio-Rad Laboratories, Inc.
- Oxford Nanopore Technologies Ltd.
- Myriad Genetics
Major Market Segments Covered:
By Product
- Instruments
- Consumables
- Services
By Technology
- Third Generation DNA Sequencing
- Next-Generation Sequencing
- Sanger Sequencing
By Application
- Clinical Investigation
- Oncology
- Forensics & Agrigenomics
- Reproductive Health
- HLA Typing
- Others
By End-Use
- Clinical Research
- Academic Research
- Biotechnology & Pharmaceutical Companies
- Hospitals & Clinics
- Others
By Geography
-
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- United Kingdom
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa
- North America
